Clinical trial
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
NCT00466843 · Office of Rare Diseases (ORD), NIH · Unknown status
Key facts
| NCT number | NCT00466843 |
|---|---|
| Title | Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome |
| Official title | Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Office of Rare Diseases (ORD), NIH |
| Collaborators | Rare Diseases Clinical Research Network |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Antithymocyte globulin (ATG), Prednisone |
| Enrollment | 54 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Apr 27, 2007 |
| Last update posted | Jun 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: